Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin

1Reno School of Medicine, University of Nevada, Reno, NV;

2Department of Neurology, Carson Tahoe Health, Carson City, NV;

3Centre for Eudaimonia and Human Flourishing, University of Oxford, Oxford, United Kingdom;

4Department of Psychiatry, University of Oxford, Oxford, United Kingdom;

5Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA;

6Keck School of Medicine, University of Southern California, Los Angeles, CA;

7Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, CA;

8Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY;

9Teachers College, Columbia University, New York, NY;

10Fermata Health, Brooklyn, NY; and

11Acacia Clinics, Sunnyvale, CA.

*Address for correspondence: Kenneth Shinozuka, BA, Centre for Eudaimonia and Human Flourishing, 7 Stoke Place, Headington, Oxford, United Kingdom OX3 9BX. E-mail: [email protected]

The authors have no conflicts of interest to declare.

B. J. Tabaac and K. Shinozuka contributed equally to this work.

留言 (0)

沒有登入
gif